Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well stated McMagyar. It’s the short term perspective versus the long term perspective and as a long term holder of shares, I believe Missling does have the shareholders best interests in mind. Would I prefer that the three trials were already up and running? Of course, but until some obvious red flag becomes apparent, I’m a retail investor who trusts the process of getting these drugs to market and have the patience and perspective for the higher payout. My biggest concern going into 2018, is protection against a hostile take over, as some here are willing to sell out on the cheap and I’m not convinced Anavex has the proper poison pill in place to prevent such an attack? With the possibility/probability that off-shored monies in this improved corporate advantaged tax environment for Mergers and Acquisitions comes home to roost, Anavex Life Sciences looks like a bigger target than ever.
A3-71 has better patent protection too from what I recall.
It states: published online December 29, 2017 which also makes me think the information came out a bit earlier. How much earlier, is unknown to me.
Like you, I’m ready for the gratification that we’ve all waited patiently for. I’m not one to make predictions of share pricing but do believe that 2018 will finally see the ball start to roll for Anavex Life Sciences. Unlike some others here, I believe CEO Missling is doing all he can in the background to ensure that the next set of trials trend positive for FDA approval.
More positives here and further validation of the Anavex pipeline...
http://www.alzheimersanddementia.com/article/S1552-5260(17)33851-7/fulltext
Anavex designed their earlier trials to fail early. We are on the right path is my belief.
You’re looking for short term gratification and need to have a long term perspective with this investment.
Per usual your comments are garbage and have no bearing on this company’s long term prospects, but please keep slinging your FUD.
With Dementia and Alzheimer’s patients, I would expect the “placebo effect” to be minimal to nonexistent. Can we just end this discussion already? It’s nonsensical.
Agreed. I can’t even recall what the current share holder “protections” entail. I know that it’s not the poison pill that the Anavex brain trust wanted.
Agreed! I enjoy your positive but reasoned perspective basparks.
26K shares
I was a buyer today!
I agree.
Love it longtime!
Remember, any new CTAD information is embargoed until the actual takes place. No leaking allowed!
A member of the AVXL FB Group was messaged by Anavex Investor Relations that the MTA with Biogen is still active.
Leave Mom out of this...I’ll settle for catastrophic engine failure.
I couldn’t agree more.
And we value your Short sighted opinion at two cents.
Vanguard increases their position in Anavex Life Sciences over the first quarter...
https://weekherald.com/2017/09/04/vanguard-group-inc-has-8-53-million-holdings-in-anavex-life-sciences-corp-avxl.html
I'm not sure if this information has already been reported but it's new to me via a Facebook group post, as follows...
An invention submitted from Dr. Missling himself approuved in the European patent register on August 3 and with some diseases which were unmentioned until now: "This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73), ANAVEX1-41 and/or Anavex19-144 in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis": https://worldwide.espacenet.com/publicationDetails/biblio?II=2&ND=3&adjacent=true&locale=en_EP&FT=D&date=20170803&CC=WO&NR=2017132127A1&KC=A1#
Much better I'd opine, based on the FDA's new directive to speed up the approval process for promising drugs and the fact that Alzheimer's Disease and dementia are the biggest drains on Medicare!
Although with Alzheimer's patients they may forget within seconds or minutes what a "placebo" is, and the fact that they even took it...rendering the placebo argument moot, save for the Caregivers.
I think it's strictly dose dependent and we should wait before any more FUD gets spread with a rogue interpretation of trial results. As I recall this chart that OFP cobbled together, has already been discussed ad nauseum. It was debunked in the past and we moved on.
At the risk of piling on here, I agree and "save yourself" kid. I'm sure poster "kund" here, could recommend some safer plays for you to quell your anxiety with AVXL.
Anavex...I think you meant!
Exactly, it's a tactical maneuver. Still conjecture but does make sense to me.
I have real money invested here, make no mistake and also value contrary opinions. Spare me the "baloney bs" when each and every piece of AVXL good news or positivity, is greeted with carefully crafted criticism and the same lingering doubts that have either been discussed ad nauseum or are merely being repeated to reach a new audience? I likewise discount the overwhelmingly optimistic "cheerleading" posts that are relentlessly positive and fail to account for adverse external market forces. Shades of grey I guess for you and me.
Of mice and men, I would argue.
Sounds like a buying opportunity to me if what you say comes to pass! Anavex long and strong...avoid employing stop losses as that strategy only serves those who seek to buy shares in the cheap. Market Makers can see where Stop Loss settings are placed and will seek them out to trigger a sale.
Would love to hear your thoughts...feel free to private message me. AVXL long term shareholder here.
There's no eroding shareholder confidence in CEO Missling from my perspective, and I have 20K plus shares into this.
Buy and hold...long term play for me. There is so much growth potential with this stock that I can afford to wait five to ten years and watch this play out.
Me too, another 8,000 shares.
Voted the "company line" via email notification and link provided. It could not have been easier and received confirmation in a follow up emailed message.
Is this new or old news as the date on the notification reads "March 10, 2014"?
More tripe from the Motley Fool. It's not worth the pixels it's "printed" with.
I see the most effective use for A2-73 going forward as a prophylactic or preventative drug for Alzheimer's, particularly for those who have a family history of Alzheimer's disease or have been identified as showing signs of Dementia and or Alzheimer's. This is not to discount A2-73's ability to bring patients "back from the brink" of more advanced Alzheimer's stages, but that level of efficacy still needs more confirmation. The fact that we can see that there were six super responders speaks to that hope and I am optimistic that for certain classes of patients, that this will be confirmed in this next P3 Trial.